Allergic Rhinitis Market Is Estimated To Record a CAGR of Around 4.12% During The Forecast Period
Evolve Business Intelligence has published a research report on the Global Allergic Rhinitis Market, 2023–2033. The global Allergic Rhinitis market is projected to exhibit a CAGR of around 4.12%during the forecast period of 2023 to 2033.
Evolve Business Intelligence has recognized the following companies as the key players in the global Allergic Rhinitis Market: GlaxoSmithKline, Sanofi, ALK-Abell, Meda Pharmaceuticals, Merck & Co., Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG).
The global Allergic Rhinitis market is projected to be valued at USD 22.32Billion by 2033, recording a CAGR of around 4.12% during the forecast period.Allergic rhinitis, commonly known as hay fever, is a type of allergic inflammation that affects the nasal passages. It is triggered by exposure to allergens, such as pollen, dust mites, pet dander, and mold spores, which cause the immune system to overreact, resulting in symptoms in the nasal passages and surrounding tissues.The hallmark symptoms of allergic rhinitis include sneezing, nasal congestion, runny nose, and itching of the nose, throat, and eyes. Other common symptoms may include watery or red eyes, post-nasal drip, cough, headache, and fatigue. In severe cases, it can also affect the sense of smell and taste and may interfere with sleep and daily activities.
The positive impact of the COVID-19 pandemic on the allergic rhinitis market is increased awareness about respiratory health and hygiene. The emphasis on handwashing, mask-wearing, and other preventive measures to reduce the spread of COVID-19 may have led to improved respiratory hygiene practices, which could potentially reduce exposure to allergens and alleviate symptoms of allergic rhinitis for some individuals.Additionally, the increased adoption of telehealth and remote healthcare services during the pandemic may have facilitated better access to healthcare for individuals with allergic rhinitis, including virtual consultations with healthcare providers, prescription refills, and delivery of medications. This could have helped some patients manage their allergic rhinitis more effectively.
The global Allergic Rhinitismarket has been segmented based on Drug Class, Route of Administration, Form,and region.
Based on the Drug Class, the Allergic Rhinitis market is segmented based on Antihistamines, Intranasal corticosteroids, and Immunotherapies. Antihistamines are expected to have the largest market share throughout the forecast period.
Based on the Route of Administration, the global Allergic Rhinitis market has been divided into Oral, Parenteral, and Intranasal. TheOralsegments are anticipated to dominate the market.
Based on Form, the global Allergic Rhinitis market has been divided into Solid, Liquid. The Solidsegments are anticipated to dominate the market.
The Allergic Rhinitis market is divided into six regions: North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. North Americanregion includes countries such as the United States and Canada and is known for its well-established healthcare infrastructure, high prevalence of allergic rhinitis, and advanced research and development in the field of allergic diseases.Europeregion comprises countries in Western Europe, Eastern Europe, and Northern Europe, including countries like Germany, France, the United Kingdom, and Russia. Europe also has a significant burden of allergic rhinitis and is home to various pharmaceutical companies involved in developing and manufacturing allergic rhinitis treatments.The Asia-Pacificregion includes countries such as China, Japan, India, Australia, and others. Asia-Pacific has a large and growing population, increasing urbanization, changing lifestyles, and environmental factors that contribute to the rising prevalence of allergic rhinitis in the region.Latin Americaregion encompasses countries in Central and South America, including Brazil, Mexico, and Argentina. Latin America has a diverse population and varying levels of healthcare infrastructure, with some countries experiencing an increasing prevalence of allergic rhinitis due to changing environmental factors.Middle Eastregion includes countries in the Middle Eastern region, such as Saudi Arabia, UAE, and Israel. Allergic rhinitis is a growing concern in the Middle East, with environmental factors such as desert dust, pollen, and indoor allergens playing a role.Africaregion comprises various countries in Africa, with differing levels of healthcare infrastructure and environmental factors. Allergic rhinitis is emerging as a significant health issue in some parts of Africa, with increasing urbanization and changing environmental factors contributing to its prevalence.